Oxford, UK – Enara Bio today announced that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®. This licensing event is a major milestone in the strategic collaboration between the companies...
Latest News
Ingelheim am Rhein, Germany – Boehringer Ingelheim on Wednesday announced a multi-target collaboration agreement with Chinese biotech Suzhou Ribo Life Science and its Swedish unit Ribocure Pharmaceuticals to develop siRNA-based treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis. The companies did not disclose what targets they would focus on, nor did...
New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine Data presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease control rate (DCR) Previously unreported results,...
VANCOUVER, Canada — Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with FOLFOX previously treated with FOLFOX/CAPOX at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January...
PARKVILLE, Missouri— Bond Biosciences, Inc., a clinical-stage, privately held biopharmaceutical company today announced a successful meeting with the U.S. Food and Drug Administration (FDA) following a scheduled pre-IND meeting with the Office of Cardiology, Hematology, Endocrinology, and Nephrology, Division of Nonmalignant Hematology to seek advice on the BBI-001 development program...
Results of a retrospective analysis showed a significantly elevated risk of bone fractures in a population-based cohort of patients with myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV), compared with the overall population. These findings were published in Leukemia and Lymphoma. The Philadelphia chromosome-negative MPNs, characterized by clonal proliferation of 1 or more...
Melbourne, Australia – A drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep apnea and needing surgery, according to a new study. The international research trial, led by Murdoch Children’s Research Institute (MCRI) and...
Orchard Park, NY – A new research perspective was published in Oncotarget in January 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.” Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in...
Little Evan Garcia slept soundly in his mother’s arms on Monday as his parents were introduced to the Aurora city employee whose anonymous bone marrow donation in 2007 saved his life. The Garcia family traveled from their Jasper, Texas, home this week to thank Mary Garza and help promote a...
COPENHAGEN, Denmark — BOOST Pharma, a clinical-stage cell biotech company focused on rare skeletal pediatric diseases, is proud to announce that new long-term data from the first-in-class BOOSTB4 stem cell therapy trial has been selected for presentation by BOOST Pharma co-founder Dr. Cecilia Götherström at the prestigious 15th International Conference...